Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 12, 2025
MONTPELLIER, France, April 18, 2025--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that the Company’s shareholders are invited to participate in the Combined General Meeting, to be held on Wednesday, May 12, 2025, at 2 pm CET in the premises of the hotel Square Louvois, located at 12, rue de Louvois, 75002, Paris, France.